- The Molnupiravir pill was designed to introduce errors into the genetic code of the virus and would be the first oral antiviral medication for COVID-19.
- Merck and partner Ridgeback Biotherapeutics are planning to seek U.S. emergency use authorisation for the pill as soon as possible and to make regulatory applications globally.
Malaysia Plans To Procure Merck Anti-Covid Pills
Malaysia has definitely been improving in terms of our health sector. With the large-scale vaccination drives resulting in a high number of fully vaccinated individuals in the nation, it’s safe to say that we are on the right track. Now, of course, the government would seek any means possible to prevent the citizens from getting infected with Covid-19. So, currently, Malaysia is in talks to procure an experimental antiviral pill developed by Merck & Co (MRK.N) for Covid-19 treatment.
According to Health Minister, Khairy Jamaluddin, in a tweet, he has started negotiations to procure the new drugs. This was done in reference to a Reuters story on Friday that the pill developed by Merck could have the chance of dying or being hospitalized for those at high risk of contracting the virus! How cool is that?
Khairy said, “As we transition to living with COVID, we will be adding new, innovative treatment options to our arsenal in addition to vaccines.”
Now, about the pills, Merck and partner Ridgeback Biotherapeutics are planning to seek U.S. emergency use authorisation for the pill as soon as possible and to make regulatory applications globally. This would then facilitate distribution amongst the global community.
Image Source : BBC
To talk in-depth about the pill, Molnupiravir; it was designed to introduce errors into the genetic code of the virus, would be the first oral antiviral medication for COVID-19. As of now, treatment options include, Gilead Sciences Inc's (GILD.O) infused antiviral Remdesivir and generic steroid Dexamethasone, both of which are generally only given once a patient has already been hospitalised.
Despite the relief that the nation’s healthcare is moving forward, there has been no immediate response to a request to clarify if the ministry's negotiations also included Gilead Sciences or Pfizer which is developing an antiviral pill with Swiss drugmaker Roche Holding AG (ROG.S).